Search

everythinglearnresearchcommunity

for

Search:↓

People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.

Targeted anticancer therapies can cause severe side effects similar to traditional chemotherapy, but with different types.

Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.

These new skin treatments are safer and more effective with minimal side effects.

Oil A formulation with Baricitinib shows promise for treating alopecia areata by promoting hair growth.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

Ritlecitinib is safe and may effectively treat alopecia areata.

The new microneedle patch effectively treats alopecia areata with fewer side effects than oral medication.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

Shorter alopecia areata episodes lead to better baricitinib treatment outcomes.

Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.

Interleukin-15 can help hair growth and protect hair follicles.

Multitarget drugs are needed to better treat complex diseases.

Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.

PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.

Combination therapies for androgenetic alopecia work best but can have significant side effects and costs.

Off-label treatments are heavily used for alopecia areata due to limited approved options.

Regenerative treatments for vitiligo show promise but need more research for long-term safety and effectiveness.

Aire mutation reduces alopecia areata, while Notch4 mutation prevents it in mice.

Blood metabolites significantly influence alopecia areata risk.

Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.

New treatments are needed for non-scarring alopecia due to current limitations.

Targeting non-Smad pathways in TGF-β signaling may improve keloid treatment.

Oral tofacitinib successfully treated total body hair loss in one patient.

Controlling inflammation can help heal diabetic foot ulcers.

Stem cell treatment from umbilical cords reduces symptoms of atopic dermatitis and may help hair growth.

Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.

Combining hyperthermia with natural compounds and conventional treatments improves cancer therapy effectiveness and reduces side effects.